Immunophenotypes [estrogen receptor (ER); progesterone receptor (PR); human epidermal growth factor receptor 2 (HER2)] in BC, were of great significance for guiding clinical treatment and judging the treatment response, disease outcome, patient recurrence and prognosis. Here, ERBB2 is linked to breast cancer.